ArticleAMB Express2026
Exploratory analysis of genotoxic Escherichia coli and Helicobacter pylori virulence in gastrointestinal carcinogenesis.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastrointestinal cancers remain among the leading causes of cancer-related mortality worldwide. Beyond environmental and hereditary determinants, increasing evidence suggests that the gut microbiota may contribute to carcinogenesis through persistent infection, expression of virulence factors, and production of genotoxic metabolites. In this context, Helicobacter pylori has been firmly implicated in gastric carcinogenesis, while colibactin-producing Escherichia coli has emerged as a potential contributor to colorectal cancer development. The aim of this study was to explore the presence of colibactin-associated E. coli and virulence factor-harboring H. pylori strains in gastrointestinal cancer patients from a Turkish cohort. Tumor samples were collected from 19 patients with colorectal cancer and 4 patients with gastric cancer. In colorectal cancer samples, the presence of colibactin was assessed by screening for key genes (clbA, clbB, clbN, and clbQ). In gastric cancer samples, major H. pylori virulence determinants, including ureA, cagA, and vacA, were evaluated. Colibactin-associated genes were detected in approximately 21% of colorectal cancer patients (4/19), whereas 75% of gastric cancer cases (3/4) were positive for H. pylori virulence factors. Whole-genome sequencing (WGS) of two colibactin-positive isolates identified them as Escherichia coli Nissle and Citrobacter braakii. Given the limited sample size and exploratory design, these results are descriptive and intended to provide preliminary insight rather than establish causality. In conclusion, this study provides early evidence supporting the potential presence of genotoxin-associated bacteria and virulent H. pylori strains in gastrointestinal cancer patients in Türkiye. These findings underscore the need for larger, well-powered, and multi-omics-integrated studies to further elucidate the role of host-microbe interactions in gastrointestinal carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.